Related Experiment Videos

Upregulated CircRNAs With Efficacy in Preclinical In Vivo Models Reveal New Targets for Therapeutic Intervention in

Satu Nahkuri1, Ulrich H Weidle2

  • 1Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland; satu.nahkuri@roche.com.

Insights

Circular RNAs (circRNAs) show promise in overcoming glioma treatment resistance. This review highlights upregulated circRNAs targeting key pathways and discusses therapeutic delivery challenges for improved glioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioma treatment efficacy requires improvement.
  • Circular RNAs (circRNAs) are implicated in various cancers.
  • Upregulated circRNAs in glioma present potential therapeutic targets.

Purpose of the Study:

  • To review the literature on upregulated circRNAs in glioma.
  • To identify circRNAs affecting glioma pathology and treatment resistance.
  • To explore therapeutic strategies involving circRNAs for glioma.

Main Methods:

  • Literature analysis of circRNAs in glioma.
  • Focus on upregulated circRNAs with preclinical efficacy.
  • Categorization of circRNAs by associated biological processes.

Main Results:

  • Identified circRNAs associated with Temozolomide (TMZ) resistance.
  • CircRNAs influencing transmembrane/secreted proteins and WNT signaling were noted.
  • CircRNAs involved in cytoskeleton dynamics and cell-matrix interactions were found.

Conclusions:

  • Upregulated circRNAs represent promising therapeutic targets for glioma.
  • Further research into circRNA functions and delivery is crucial.
  • Development of targeted therapies using circRNAs could enhance glioma treatment outcomes.